Assays to Detect Neurofilament Light

EP: 1.The Value of Biomarker in Multiple Sclerosis

EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis

Now Viewing

EP: 3.Assays to Detect Neurofilament Light

EP: 4.Challenges and Opportunity With MRI

EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions

EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care

EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI

EP: 8.How to Address Increasing Neurofilament Light Chain Levels

EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels

EP: 10.Monitoring Patients After a Change in Treatment Regimen

EP: 11.Assessing Lesion Types With MS Biomarkers

EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease

EP: 13.The CLIMB Study

EP: 14.Reimbursement for MRI

EP: 15.Understanding the Underlying Progression of Multiple Sclerosis

EP: 16.Biomarkers, Patient Communication, and the Future of Care

EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers

Mark Freedman, MD, MSc, addresses the historical measurement of neurofilament light chain (NFL) in spinal fluid due to higher levels, necessitating lumbar punctures. He directs the question to Tanuja Chitnis, MD, who explains the advancements in the past 5 to 10 years, notably the use of ultra-sensitive assays like single-molecule array assays (SIMOA).

Tanuja Chitnis, MD, highlights the significant progress with SIMOA, allowing the detection of extremely low levels of proteins, including NFL, in the blood. She emphasizes the correlation between NFL levels in spinal fluid and blood, noting a robust 60% correlation or a correlation coefficient of about 0.6. This correlation supports the reliability of NFL measurement in the blood as a biomarker.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.